Tag: Biomarker

PC14586 Targets Previously “Undruggable” p53 in Treatment of Solid Tumors

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.

November 27, 2023 9:00 am

By Kyle Doherty

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity. With the initiation of the phase … Read more

Raludotatug Deruxtecan Elicits Early Efficacy and Safety in Platinum-Resistant Ovarian Cancer

November 17, 2023 9:00 am

Clearity’s Perspective: A phase I clinical trial studying the antibody-drug conjugate (ADC) raludotatug deruxtecan (DS-6000a, R-DXd) shows early encouraging activity in heavily pretreated ovarian cancer. The antibody portion of raludotatug deruxtecan targets CDH6 (found in about 65-85% of ovarian cancers) … Read more

Scientists Piece Together DNA Repair Pathway Implicated in Breast, Ovarian, and Prostate Cancers

November 15, 2023 9:00 am

Clearity’s Perspective: Cancer cells that have mutations in BRCA or that are HRD-positive are not able to use the so-called homologous recombination repair pathway to fix mistakes in the cancer cell. These cancer cells become reliant on other repair pathways. … Read more

Liquid Biopsy Shows Promise to Distinguish Benign Pelvic Masses from Tumorous Ones

October 11, 2023 9:00 am

A new liquid biopsy test developed by researchers at USC Norris Comprehensive Cancer Center has shown promise to distinguish which pelvic masses are benign and which are tumorous, a development that could aid early diagnosis of high-grade serous ovarian carcinoma … Read more

First Blood Test for Dozens of Hereditary Cancers Approved by FDA

October 2, 2023 9:00 am

The FDA has approved the first blood test that can help identify hundreds of potentially cancer-associated hereditary variants. The Invitae Common Hereditary Cancers Panel evaluates a blood sample to identify DNA variants in 47 genes associated with an elevated risk … Read more

Clinical trial gives women with gene mutation power over disease

September 8, 2023 9:00 am

Shared by Norma Rabago

When Juana Padron, a 40-year-old mother of four, chose to have a genetic test, going against her friends and family’s advice was the last thing on her mind.

Padron’s aunt died from breast cancer, and she … Read more

New biomarker offers hope for earlier ovarian cancer detection

August 9, 2023 9:00 am

Ovarian cancer is particularly difficult to detect, as the disease often does not produce significant symptoms until it has reached late stages and caused metastasis. New screening methods would help physicians detect ovarian tumors early and dramatically increase the chances … Read more

Protein Discovery Aids Ovarian Cancer Detection

July 7, 2023 9:00 am

In Science Advances, Nagoya University scientists publish their work discovering three membrane proteins associated with ovarian cancer. The research team are hopeful that their discovery could improve approaches for detecting and diagnosing the disease.

Reliable biomarkers lacking for ovarian

… Read more

Ovarian Cancer in Black and African American Communities

February 3, 2023 3:10 pm

Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed … Read more

Restoring the gut biome after antibiotics could lead to better outcomes for ovarian cancer patients

November 8, 2022 11:09 am

by Cleveland Clinic

Reassessing antibiotic dosage and type could improve survival rates in deadliest gynecologic malignancy, Cleveland Clinic research finds

Newswise — CLEVELAND – Antibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression … Read more

Elizabeth Swisher, MD, on Predicting Therapy Benefits in Ovarian Cancer

October 5, 2022 4:42 pm

by Mark L. Fuerst

– KELIM score can now be used to look at upfront response, study showed

Tumor primary chemosensitivity testing can help determine if ovarian cancer patients need a boost along with first-line chemotherapy. In the VELIA trial, … Read more

Ovarian Cancer Detection Takes a Step Forward

September 12, 2022 1:45 pm

A new type of technology can capture stray ovarian cancer cells from a simple blood test and successfully predict cancer in people who have a lesion or cyst in the pelvic region, according to a new study by a Wilmot … Read more

Epigenetic ‘Priming’ Boosts Cancer Immunotherapy

July 25, 2022 11:11 am

by Will Doss

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, making them more suitable for treatment with immunotherapy, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

This could … Read more

Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response

July 7, 2022 10:30 am

NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.

For … Read more

MD Anderson Researchers Present Encouraging Results of Early-Stage Clinical Trials at 2022 ASCO Annual Meeting

June 7, 2022 10:45 am

by University of Texas M.D. Anderson Cancer Center

Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more

Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor

June 5, 2022 9:55 am

by Caroline Hopkins

CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.

The drug, which AstraZeneca licensed from Merck in … Read more

A Sensor Sniffs for Cancer, Using Artificial Intelligence

May 12, 2022 9:51 am

Biomedical engineer Daniel Heller leads the Cancer Nanomedicine Laboratory at MSK. 

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed a sensor that can be trained to sniff for cancer, with the help of artificial intelligence.

Although the training … Read more

Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer

April 27, 2022 12:40 pm

by Matthew Stenger

In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in … Read more

Biomarkers Found for Platinum Resistance in Gynecologic Cancer

November 19, 2021 11:56 am

Blood-based metabolic signatures may predict whether women with ovarian or uterine cancer will respond well to platinum-based chemotherapy, according to a study by researchers in the Department of Gynecology at the Federal University of São Paulo’s Medical School (EPM-UNIFESP) in … Read more

MCW scientists uncover potential therapeutic target and biomarker for ovarian cancerPortfolio Inspiration

November 17, 2021 11:28 am

MEDICAL COLLEGE OF WISCONSIN

The study’s findings suggest targeting protein FXR1 to inhibit the progression of the cMYC oncogene, a gene mutation often over-expressed in patients with ovarian cancer

Scientists at the Medical College of Wisconsin (MCW) Cancer Center and … Read more